Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Breast12
NCT04739761Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2021
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 18
01
Overview
Phase 3, open-label trial of trastuzumab deruxtecan in breast cancer (2 cohorts), sponsored by AstraZeneca. Primary endpoints: Objective Response Rate and Progression-Free Survival Rate at 12 months. Started Jun 2021; status: active, not recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04739761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04739761.